1. Technical Field
Embodiments of the present invention relate generally to cryotherapy and brachytherapy and, more particularly, to combined cryotherapy and brachytherapy methods and devices.
2. Description of Related Art
Several approaches to cancer treatment are known. The most common and effective approaches include: surgery, chemotherapy, radiation therapy, and cryotherapy. These approaches may be administered individually, in various combinations, and/or in succession. Often, a combination of cancer treatment approaches yields the most effective results.
Each cancer treatment option has positive aspects and drawbacks. For example, radiation therapy, which uses high-energy rays or particles to destroy cancer cells, can damage nearby healthy tissue along with the cancer cells because it is difficult to administer accurately. Chemotherapy, which uses drugs to kill cancer cells, is also difficult to administer accurately and locally because chemotherapy drugs are toxic to both normal and cancerous cells.
Radiation therapy is a primary cancer treatment. It can be administered externally or internally. Externally, radiation may be administered via external beam therapy (EBT), in which high-energy x-ray beams are directed at the tumor from outside the body. Internally, radiation may be administered via brachytherapy, in which one or more pellets or “seeds” of radioactive material are placed in, or adjacent to, a tumor.
A key feature of brachytherapy is that the irradiation is localized around the radiation source. Exposure to radiation of healthy tissues further away from the sources is therefore reduced. The result is the ability to use a higher total dose of radiation to treat a smaller area and in a shorter time than is possible with external radiation treatment.
Cryotherapy can be a particularly advantageous cancer treatment because it does not use radiation and is direct treatment that kills only the targeted tissue. Additionally, cryotherapy requires a small incision and causes less trauma. With cryotherapy, one or more thin needles are inserted into the tumor and the needles are cooled using extremely cold liquids or using high-pressure gas. The needles are cooled so as to form ice balls at the tips. These iceballs freeze and kill the tumor. Thus, the problems of irradiation are avoided.
Two common cancers that may be treated via brachytherapy and cryotherapy are prostate and breast cancer.
Conventional breast cancer treatment, for example, can include a surgical approach and an additional approach. First, a tumor is removed by surgery (a lumpectomy) followed by external radiation therapy. In recent years, there has been a trend to replace external radiation therapy with internal radiation therapy, like brachytherapy.
Brachytherapy, in the treatment of breast cancer, is performed by positioning a balloon in the void of the removed tumor, and then placing one or more radiation sources (seeds) in the balloon. Typically, the balloon is positioned once during surgery. Thereafter, the seed may be replaced or removed, as required. Accurate positioning of the source in the same place is important.
Cryotherapy and other emerging tumor ablation techniques are investigated as replacement to the surgical component (lumpectomy) in treatment of breast cancer. One challenge is that when the tumor is ablated rather than surgically removed, there is no room (void) for a brachytherapy balloon. Presently there is no brachytherapy solution for breast tumors that does not feature such a balloon.
Among the advantages of using a removable radioactive source in a balloon, rather than permanently implanting a radioactive source, is that higher radiation doses may be used.
The background art does not provide a breast brachytherapy solution that does not feature a balloon. Furthermore, it does not provide a removable brachytherapy solution that can be used following cryotherapy treatment.
Embodiments of the present invention provide either a device or a method for combination cryotherapy and brachytherapy, which does not require a brachytherapy balloon.
Various non-limiting embodiments according to the present invention of a combined cryotherapy and brachytherapy device are described herein.
One aspect of the present invention provides a combined brachytherapy and ablation method, including: inserting an ablation device into tissue of a subject; ablating tissue within an ablation zone of the device; detaching and removing a first part of the device while leaving a second part of the device in the tissue, the first part contacting the ablation zone; and inserting a brachytherapy rod into the second part of the device when the second part is detached from the first part, the brachytherapy rod connected to base at one end and retaining a radioactive seed at an opposing end, the brachytherapy rod configured and dimensioned so that when it is inserted into the device up to the base, the radioactive seed is in the ablation zone. The seed dimensions may vary from sub-milimeters up to a few centimeters long.
Another aspect of the present invention provides a combined cryotherapy and brachytherapy method, including: inserting an ablation device into a tumor; ablating a zone that engulfs the tumor; detaching a part of the ablation device from the rest of the ablation device; fixing the detached part at a specified location in contact with the ablation zone; and placing at least one radioactive seed in a specified location in the detached part and in the ablation zone.
Still another aspect of the present invention provides a combined cryotherapy and brachytherapy method, including: ablating tissue in an ablation zone of a cryoprobe inserted into a tumor; separating at least a portion of the cryprobe from a handle; fixing a location of the at least a portion of the cryoprobe in the ablation zone; and positioning at least one radioactive element in the at least a portion of the cryprobe, after the ablating.
Yet another aspect of the present invention provides a device, including: a handle; a cryoprobe that is selectively detachable from the handle and has an ablation zone when activated; a brachytherapy rod adapted and configured to be removably insertable into at least a portion of the cryoprobe when it is detached from the handle, the rod having at least one radioactive seed at an end. When the brachytherapy rod is inserted into the cryoprobe, the at least one radioactive seed is disposed at a specified position in the ablation zone.
A further aspect of the present invention provides a tumor treatment method, including; encompassing a tumor in an ablation zone of an ablation device; ablating tissue in the ablation zone; and inserting a radiation source into the ablation zone via the ablation device.
These, additional, and/or other aspects and/or advantages of the present invention are set forth in the detailed description which follows; possibly inferable from the detailed description; and/or learnable by practice of the present invention.
Embodiments of the present invention are herein described, by way of examples only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the like elements throughout. The embodiments are described below to explain the present invention by referring to the figures.
Before explaining any exemplary embodiments of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. Rather, the invention is capable of other embodiments and/or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Referring now to
As is known, an associated ablation zone of a cryoprobe is a function of the configuration of the cryoprobe and how it is used. Using differently configured cryoprobes yields differently shaped ablation zones. Thus, desired ablation zone (one that engulfs a tumor) is achievable by selecting an appropriate cryoprobe and how it is used.
The part or parts of the ablation device that come(s) in contact with the patient are preferably constructed of a biocompatible material that can reside within the body for several days. This is in contrast to conventional ablation devices that are only in a body for a few minutes.
In order to accurately position a radiation source in an ablation zone, the device 100 includes a mechanism that ensures correct position of the radiation source(s) when the user located them in the cryoprobe 104.
Referring to
It is preferable to position the seed in the center 106 of the ablation zone 105.
Optionally, as illustrated in
Optionally, the base 208 of the rod 209 may be dimensioned so as to prevent the rod from entering too deeply into the cryoprobe 104.
It is to be understood that the seed-retaining portion 206 need not be located at the opposing end 211. Indeed, as
Alternatively, the seed-retaining portion 206 may be configured to retain multiple seeds 210, as
Optionally, as illustrated in
In operation, a user of the device 100 ablates the tissue in the ablation zone 105, which engulfs the tumor 103, and positions a radiation source 210 in the ablation zone 105. Several approaches to position the radiation source 210 are available.
One example is illustrated in
Another example is illustrated in
After an ablation process is completed, the cryoprobe 104 is detached from the handle 101, and the radiation source 210 is delivered through the detached cryoprobe 104. Alternatively, as
In other embodiments, the ablation device may use another ablation technology. Non-limiting examples of ablation technologies include RF, microwave, and laser.
Preferably, when multiple seeds are used during a multi-day treatment, the ablation device is securely attached to the tissue. This may be done by special retractable needles that extend from the ablation device into the tissue, or by a special cover 311 that attaches the external part of the ablation device to the skin 102. Optionally, a cover 311 may be applied to cover the base 208 in a multi-day treatment.
Referring now to
In operation 510, it is particularly advantageous to insert the ablation device into the tumor under imaging guidance. Non-limiting examples of systems that may provide such guidance include ultrasound, MRI, CT, and X-ray.
In operation 540, it is preferable to fix the detachable part substantially in the center of the ablated zone. As
In operation 550, one or more seeds may be positioned in the detachable part. When more than one seed is placed, the various seeds may share the same intensity and profile.
The method 500, or portions thereof, may be repeated as necessary and/or desired to achieve a desired result.
The method 500 may be performed with the device 100 of
Advantageously and optionally, when the method 500 is performed via the device 100 of
By way of non-limiting example, the radiation source(s) 210 may be placed at specified locations with respect to the distal end of the rod 209, 209′, or 209″. As a result, when the rod is fully inserted into the cryoprobe 104, it reaches the tip 107 and stops. The location(s) of the radiation source(s) may be determined by the distance between the inner part of the tip 107 of the cryoprobe 104 and the center 106 of the ablation zone 5. Alternatively, the rod 209′ may be inserted until protrusion 209a contacts cryoprobe 104.
As the foregoing illustrates, embodiments of the present invention provide a device that features a removable cryogenic device that is insertable to an area of tissue to be treated, such as for example in the breast, for treatment of a tumor. The device may feature a removable core that includes a shaft for receiving a cryogen and a tip for being cooled by the cryogen and for being inserted to the tissue to be treated. After cryogenic treatment, the removable core is removed from the device and a radiation source is inserted through the device to the tissue to be treated. In place of a balloon as is known in the art, the cryoprobe portion of the device, the tip of which cryogenically freezes the tissue, receives the radiation source. The core may optionally surround at least a proximal part of the cryoprobe portion and/or may optionally be removably connected to the cryoprobe portion, for example.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
The various described embodiments and/or examples may be combined.
Although at least one selected embodiment of the present invention has been shown and described, it is to be understood the present invention is not limited to the described embodiment(s). Instead, it is to be appreciated that changes may be made to this/these embodiment(s) without departing from the principles and spirit of the invention, the scope of which is defined by the claims and the equivalents thereof.
This application claims the benefit of U.S. provisional patent application No. 61/159,497, filed Mar. 12, 2009.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3234746 | Smith | Feb 1966 | A |
| 3358472 | Kipling | Dec 1967 | A |
| 3664344 | Bryne | May 1972 | A |
| 3699775 | Cowans | Oct 1972 | A |
| 3712306 | Bryne | Jan 1973 | A |
| 3736936 | Basiulis | Jun 1973 | A |
| 3800552 | Sollami | Apr 1974 | A |
| 3862630 | Balamuth | Jan 1975 | A |
| 3882849 | Jamshidi | May 1975 | A |
| 3938505 | Jamshidi | Feb 1976 | A |
| 3971383 | Van Gerven | Jul 1976 | A |
| 4082096 | Benson | Apr 1978 | A |
| 4091634 | Shepherd | May 1978 | A |
| 4127903 | Schachar | Dec 1978 | A |
| 4200104 | Harris | Apr 1980 | A |
| 4211231 | Rzasa | Jul 1980 | A |
| 4279626 | Buchmuller | Jul 1981 | A |
| 4306568 | Torre | Dec 1981 | A |
| 4313306 | Torre | Feb 1982 | A |
| 4367744 | Sole | Jan 1983 | A |
| 4428748 | Peyman | Jan 1984 | A |
| 4463458 | Seidner | Aug 1984 | A |
| 4481948 | Sole | Nov 1984 | A |
| 4487253 | Malek | Dec 1984 | A |
| 4552208 | Sorensen | Nov 1985 | A |
| 4570626 | Norris | Feb 1986 | A |
| 4573525 | Boyd | Mar 1986 | A |
| 4611654 | Buchsel | Sep 1986 | A |
| 4617018 | Nishi | Oct 1986 | A |
| 4676225 | Bartera | Jun 1987 | A |
| 4726194 | Mackay | Feb 1988 | A |
| 4765396 | Seidenberg | Aug 1988 | A |
| 4770171 | Sweren | Sep 1988 | A |
| 4802475 | Weshahy | Feb 1989 | A |
| 4831856 | Gano | May 1989 | A |
| 5026387 | Thomas | Jun 1991 | A |
| 5047043 | Kubota | Sep 1991 | A |
| 5108390 | Potocky | Apr 1992 | A |
| 5147355 | Friedman | Sep 1992 | A |
| 5188102 | Idemoto | Feb 1993 | A |
| 5214925 | Hoy | Jun 1993 | A |
| 5222937 | Kagawa | Jun 1993 | A |
| 5224943 | Goddard | Jul 1993 | A |
| 5243826 | Longsworth | Sep 1993 | A |
| 5254082 | Takase | Oct 1993 | A |
| 5254116 | Baust | Oct 1993 | A |
| 5261923 | Soares | Nov 1993 | A |
| 5263957 | Davison | Nov 1993 | A |
| 5264116 | Apelian | Nov 1993 | A |
| 5267960 | Hayman et al. | Dec 1993 | A |
| 5275595 | Dobak | Jan 1994 | A |
| 5281215 | Milder | Jan 1994 | A |
| 5295484 | Marcus | Mar 1994 | A |
| 5324286 | Fowle | Jun 1994 | A |
| 5330745 | Mcdow | Jul 1994 | A |
| 5334181 | Rubinsky | Aug 1994 | A |
| 5342380 | Hood | Aug 1994 | A |
| 5361591 | Caldwell | Nov 1994 | A |
| 5391144 | Sakurai | Feb 1995 | A |
| 5411374 | Gram | May 1995 | A |
| 5417073 | James | May 1995 | A |
| 5423807 | Milder | Jun 1995 | A |
| 5429138 | Jamshidi | Jul 1995 | A |
| 5438837 | Caldwell | Aug 1995 | A |
| 5441512 | Muller | Aug 1995 | A |
| 5445462 | Johnson | Aug 1995 | A |
| 5452582 | Longsworth | Sep 1995 | A |
| 5488831 | Griswold | Feb 1996 | A |
| 5516505 | Mcdow | May 1996 | A |
| 5520682 | Baust | May 1996 | A |
| 5526821 | Jamshidi | Jun 1996 | A |
| 5547473 | Peyman | Aug 1996 | A |
| 5573532 | Chang | Nov 1996 | A |
| 5600143 | Roberts | Feb 1997 | A |
| 5647868 | Chinn | Jul 1997 | A |
| 5654279 | Rubinsky | Aug 1997 | A |
| 5658276 | Griswold | Aug 1997 | A |
| 5674218 | Rubinsky | Oct 1997 | A |
| 5683592 | Bartholomew et al. | Nov 1997 | A |
| 5687776 | Forgash | Nov 1997 | A |
| 5716353 | Matsuura | Feb 1998 | A |
| 5720743 | Bischof | Feb 1998 | A |
| 5728130 | Ishikawa | Mar 1998 | A |
| 5735845 | Zupkas | Apr 1998 | A |
| 5771946 | Kooy | Jun 1998 | A |
| 5787940 | Bonn | Aug 1998 | A |
| 5800448 | Banko | Sep 1998 | A |
| 5800487 | Mikus | Sep 1998 | A |
| 5814040 | Nelson | Sep 1998 | A |
| 5868673 | Vesely | Feb 1999 | A |
| 5885276 | Ammar | Mar 1999 | A |
| 5899897 | Rabin | May 1999 | A |
| 5906612 | Chinn | May 1999 | A |
| 5906628 | Miyawaki | May 1999 | A |
| 5910104 | Dobak | Jun 1999 | A |
| 5921982 | Lesh | Jul 1999 | A |
| 4946460 | Merry | Aug 1999 | A |
| 5976092 | Chinn | Nov 1999 | A |
| 5976505 | Henderson | Nov 1999 | A |
| 5992158 | Goddard | Nov 1999 | A |
| 6012453 | Tsals | Jan 2000 | A |
| 6024750 | Mastri | Feb 2000 | A |
| 6027499 | Johnston | Feb 2000 | A |
| 6032068 | Daniel | Feb 2000 | A |
| 6032675 | Rubinsky | Mar 2000 | A |
| 6035657 | Dobak | Mar 2000 | A |
| 6036667 | Manna | Mar 2000 | A |
| 6039730 | Rabin | Mar 2000 | A |
| 6041787 | Rubinsky | Mar 2000 | A |
| 6042342 | Orian | Mar 2000 | A |
| 6053906 | Honda | Apr 2000 | A |
| 6059820 | Baronov | May 2000 | A |
| 6063098 | Houser | May 2000 | A |
| 6095149 | Sharkey | Aug 2000 | A |
| 6142991 | Schatzberger | Nov 2000 | A |
| 6152894 | Kubler | Nov 2000 | A |
| 6182666 | Dobak | Feb 2001 | B1 |
| 6200308 | Pope | Mar 2001 | B1 |
| 6206832 | Downey | Mar 2001 | B1 |
| 6212904 | Arkharov | Apr 2001 | B1 |
| 6216029 | Paltieli | Apr 2001 | B1 |
| 6235018 | LePivert | May 2001 | B1 |
| 6237355 | Li | May 2001 | B1 |
| 6251105 | Mikus | Jun 2001 | B1 |
| 6270494 | Kovalcheck | Aug 2001 | B1 |
| 6280407 | Manna | Aug 2001 | B1 |
| 6354088 | Emmer | Mar 2002 | B1 |
| 6355033 | Moorman | Mar 2002 | B1 |
| 6358264 | Banko | Mar 2002 | B2 |
| 6379348 | Onik | Apr 2002 | B1 |
| 6383180 | Lalonde | May 2002 | B1 |
| 6383181 | Johnston | May 2002 | B1 |
| 6411852 | Danek | Jun 2002 | B1 |
| 6413263 | Lobdill | Jul 2002 | B1 |
| 6423009 | Downey | Jul 2002 | B1 |
| 6432102 | Joye | Aug 2002 | B2 |
| 6457212 | Craig | Oct 2002 | B1 |
| 6468268 | Abboud | Oct 2002 | B1 |
| 6468269 | Korpan | Oct 2002 | B1 |
| 6471217 | Hayfield | Oct 2002 | B1 |
| 6482178 | Andrews | Nov 2002 | B1 |
| 6497714 | Ishikawa | Dec 2002 | B1 |
| 6500109 | Tokita | Dec 2002 | B2 |
| 6503246 | Har-Shai | Jan 2003 | B1 |
| 6508814 | Tortal | Jan 2003 | B2 |
| 6513336 | Zurecki | Feb 2003 | B2 |
| 6547784 | Thompson | Apr 2003 | B1 |
| 6551309 | LePivert | Apr 2003 | B1 |
| 6562030 | Abboud | May 2003 | B1 |
| 6565556 | Korpan | May 2003 | B1 |
| 6581390 | Emmer | Jun 2003 | B2 |
| 6582426 | Moorman | Jun 2003 | B2 |
| 6631615 | Drube | Oct 2003 | B2 |
| 6640556 | Ursan | Nov 2003 | B2 |
| 6659730 | Gram | Dec 2003 | B2 |
| 6659956 | Barzell | Dec 2003 | B2 |
| 6672095 | Luo | Jan 2004 | B1 |
| 6678621 | Wiener et al. | Jan 2004 | B2 |
| 6682525 | Lalonde | Jan 2004 | B2 |
| 6698423 | Honkonen | Mar 2004 | B1 |
| 6702761 | Damadian | Mar 2004 | B1 |
| 6761715 | Carroll | Jul 2004 | B2 |
| 6765333 | Mariaucue | Jul 2004 | B1 |
| 6768917 | Van Vaals | Jul 2004 | B1 |
| 6772766 | Gallo | Aug 2004 | B2 |
| 6786902 | Rabin | Sep 2004 | B1 |
| 6824543 | Lentz | Nov 2004 | B2 |
| 6852706 | Heber-Katz | Feb 2005 | B1 |
| 6858025 | Maurice | Feb 2005 | B2 |
| 6866624 | Chornenky et al. | Mar 2005 | B2 |
| 6869439 | White | Mar 2005 | B2 |
| 6889695 | Pankratov | May 2005 | B2 |
| 6898940 | Gram | May 2005 | B2 |
| 6908472 | Wiener | Jun 2005 | B2 |
| 6910510 | Gale | Jun 2005 | B2 |
| 6913604 | Mihalik | Jul 2005 | B2 |
| 6918869 | Shaw et al. | Jul 2005 | B2 |
| 6932771 | Whitmore | Aug 2005 | B2 |
| 6936045 | Yu | Aug 2005 | B2 |
| 6942659 | Lehmann | Sep 2005 | B2 |
| 6951569 | Nohilly | Oct 2005 | B2 |
| 6954977 | Maguire | Oct 2005 | B2 |
| 6995493 | Isoda | Feb 2006 | B2 |
| 7001378 | Yon | Feb 2006 | B2 |
| 7025762 | Johnston | Apr 2006 | B2 |
| 7025767 | Schaefer | Apr 2006 | B2 |
| 7071690 | Butts | Jul 2006 | B2 |
| 7081111 | Svaasand | Jul 2006 | B2 |
| 7101367 | Xiao et al. | Sep 2006 | B2 |
| 7128739 | Prakash et al. | Oct 2006 | B2 |
| 7144228 | Emmer | Dec 2006 | B2 |
| 7151374 | Doty | Dec 2006 | B2 |
| 7160291 | Damasco | Jan 2007 | B2 |
| 7160292 | Moorman | Jan 2007 | B2 |
| 7165422 | Little | Jan 2007 | B2 |
| 7189228 | Eum | Mar 2007 | B2 |
| 7207985 | Duong | Apr 2007 | B2 |
| 7213400 | Dickerson | May 2007 | B2 |
| 7223080 | Duron | May 2007 | B2 |
| 7250046 | Fallat | Jul 2007 | B1 |
| 7252648 | Honda | Aug 2007 | B2 |
| 7255693 | Johnston | Aug 2007 | B1 |
| 7273479 | Littrup | Sep 2007 | B2 |
| 7278991 | Morris | Oct 2007 | B2 |
| 7280623 | Gupta | Oct 2007 | B2 |
| 7282919 | Doty | Oct 2007 | B2 |
| 7288089 | Yon | Oct 2007 | B2 |
| 7318327 | Dickerson | Jan 2008 | B2 |
| 7344530 | Bischoff | Mar 2008 | B2 |
| 7344531 | Bischoff | Mar 2008 | B2 |
| 7354434 | Zvuloni | Apr 2008 | B2 |
| 7361187 | Duong | Apr 2008 | B2 |
| 7381207 | Duong | Jun 2008 | B2 |
| 7458968 | Carroll | Dec 2008 | B2 |
| 7485117 | Damasco | Feb 2009 | B2 |
| 7498812 | Doty | Mar 2009 | B2 |
| 7510554 | Duong | Mar 2009 | B2 |
| 7563260 | Whitmore | Jul 2009 | B2 |
| 20010047129 | Hall et al. | Nov 2001 | A1 |
| 20020016540 | Mikus et al. | Feb 2002 | A1 |
| 20020022832 | Mikus et al. | Feb 2002 | A1 |
| 20020040220 | Zvuloni et al. | Apr 2002 | A1 |
| 20020077654 | Javier | Jun 2002 | A1 |
| 20020085921 | Gram | Jul 2002 | A1 |
| 20020144509 | Chalk | Oct 2002 | A1 |
| 20020156469 | Yon | Oct 2002 | A1 |
| 20020157402 | Drube | Oct 2002 | A1 |
| 20020160640 | Korpan | Oct 2002 | A1 |
| 20020161385 | Wiener | Oct 2002 | A1 |
| 20030060762 | Zvuloni | Mar 2003 | A1 |
| 20030079480 | Emmer | May 2003 | A1 |
| 20030126867 | Drube | Jul 2003 | A1 |
| 20030135119 | Lee et al. | Jul 2003 | A1 |
| 20030181897 | Thomas | Sep 2003 | A1 |
| 20030220635 | Knowlton | Nov 2003 | A1 |
| 20040024391 | Cytron | Feb 2004 | A1 |
| 20040055316 | Emmer et al. | Mar 2004 | A1 |
| 20040078033 | Levin | Apr 2004 | A1 |
| 20040215178 | Maurice | Oct 2004 | A1 |
| 20050016185 | Emmer | Jan 2005 | A1 |
| 20050038422 | Maurice | Feb 2005 | A1 |
| 20050056027 | White | Mar 2005 | A1 |
| 20050086949 | Noble | Apr 2005 | A1 |
| 20050106153 | Nordouist | May 2005 | A1 |
| 20050177147 | Vancelette | Aug 2005 | A1 |
| 20050192564 | Cosman et al. | Sep 2005 | A1 |
| 20050214268 | Cavanagh | Sep 2005 | A1 |
| 20050274142 | Corey | Dec 2005 | A1 |
| 20060049274 | Hume | Mar 2006 | A1 |
| 20060053165 | Hume | Mar 2006 | A1 |
| 20060079867 | Berzak | Apr 2006 | A1 |
| 20060122590 | Bliweis | Jun 2006 | A1 |
| 20060155267 | Berzak | Jul 2006 | A1 |
| 20060155268 | Amir | Jul 2006 | A1 |
| 20060264920 | Duong | Nov 2006 | A1 |
| 20060293647 | McRae | Dec 2006 | A1 |
| 20070000259 | Brook | Jan 2007 | A1 |
| 20070093710 | Maschke | Apr 2007 | A1 |
| 20070123815 | Mark | May 2007 | A1 |
| 20070129626 | Mahesh | Jun 2007 | A1 |
| 20070129629 | Beauregard | Jun 2007 | A1 |
| 20070149959 | DeLonzor | Jun 2007 | A1 |
| 20070153969 | Maschke | Jul 2007 | A1 |
| 20070166171 | Kondo | Jul 2007 | A1 |
| 20070167939 | Duong | Jul 2007 | A1 |
| 20070276360 | Johnston | Nov 2007 | A1 |
| 20080027419 | Hamel | Jan 2008 | A1 |
| 20080051774 | Ofir | Feb 2008 | A1 |
| 20080051776 | Bliweis | Feb 2008 | A1 |
| 20080115509 | Gullickson | May 2008 | A1 |
| 20080119834 | Vancelette | May 2008 | A1 |
| 20080119838 | Vancelette | May 2008 | A1 |
| 20080140061 | Toubia et al. | Jun 2008 | A1 |
| 20080319433 | Geiselhart | Dec 2008 | A1 |
| 20090011032 | LePivert | Jan 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 2437079 | Jun 2004 | CA |
| 202004008875 | Aug 2004 | DE |
| 102005050344 | May 2007 | DE |
| 0292922 | Nov 1988 | EP |
| 395307 | Oct 1990 | EP |
| 570301 | Nov 1993 | EP |
| 955012 | Nov 1999 | EP |
| 919197 | Feb 2005 | EP |
| 1108905 | Apr 1968 | GB |
| 1402737 | Aug 1975 | GB |
| 1473856 | May 1977 | GB |
| 1534472 | Dec 1978 | GB |
| 2336781 | Nov 1999 | GB |
| 2409815 | Jul 2005 | GB |
| 2004041428 | Feb 2004 | JP |
| 2007144180 | Jun 2007 | JP |
| 2007167100 | Jul 2007 | JP |
| WO8303961 | Nov 1983 | WO |
| WO9637158 | Nov 1996 | WO |
| WO9639960 | Dec 1996 | WO |
| WO9947876 | Sep 1999 | WO |
| WO0137919 | May 2001 | WO |
| WO0141683 | Jun 2001 | WO |
| WO0197702 | Dec 2001 | WO |
| WO0202026 | Jan 2002 | WO |
| WO03015651 | Feb 2003 | WO |
| WO2004051409 | Aug 2004 | WO |
| WO0189183 | Oct 2004 | WO |
| WO2004060465 | Feb 2005 | WO |
| WO2004093635 | Jun 2005 | WO |
| WO2005098308 | Oct 2005 | WO |
| WO2005000106 | Dec 2005 | WO |
| WO2006116457 | Nov 2006 | WO |
| WO2006127467 | Nov 2006 | WO |
| WO2007028232 | Mar 2007 | WO |
| WO2007086056 | Aug 2007 | WO |
| WO2007129308 | Nov 2007 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20100234670 A1 | Sep 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61159497 | Mar 2009 | US |